Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Argenx Se ADR
(NQ:
ARGX
)
514.23
-3.09 (-0.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
October 28, 2022
Wedbush raised McDonald's Corporation (NYSE: MCD) price target from $265 to $300. Wedbush analyst Nick Setyan maintained the stock with an Outperform rating. McDonald's shares rose 3.3% to close at...
Via
Benzinga
Recap: argenx Q3 Earnings
October 27, 2022
argenx (NASDAQ:ARGX) reported its Q3 earnings results on Thursday, October 27, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx missed estimated earnings by...
Via
Benzinga
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022
From
argenx SE
Via
GlobeNewswire
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
October 20, 2022
From
argenx SE
Via
GlobeNewswire
7 Analysts Have This to Say About argenx
October 18, 2022
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Argenx's Drug Scores European Approval For Muscular Fatigue Disorder
August 11, 2022
Via
Benzinga
Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike
July 29, 2022
Via
Benzinga
argenx: Q2 Earnings Insights
July 28, 2022
argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
October 12, 2022
Upgrades
Via
Benzinga
Recap: argenx Q2 Earnings
July 28, 2022
argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
What 5 Analyst Ratings Have To Say About argenx
July 25, 2022
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter:
Via
Benzinga
SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space
May 24, 2022
Via
Benzinga
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
September 29, 2022
Via
Benzinga
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection
September 21, 2022
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 11, 2022
Via
Benzinga
Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate
August 11, 2022
The European Commission (EC) has granted marketing authorization for Argenx’s (NASDAQ: ARGX) lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
July 29, 2022
Via
Benzinga
Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study
May 05, 2022
Via
Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
July 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
July 28, 2022
From
argenx SE
Via
GlobeNewswire
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
July 28, 2022
From
argenx SE
Via
GlobeNewswire
Piper Sandler Maintains Overweight Rating for argenx: Here's What You Need To Know
July 25, 2022
Piper Sandler has decided to maintain its Overweight rating of argenx (NASDAQ:ARGX) and raise its price target from $415.00 to $425.00. Shares of argenx are trading up 1.84% over the last 24 hours, at...
Via
Benzinga
Recap: argenx Q1 Earnings
May 05, 2022
argenx (NASDAQ:ARGX) reported its Q1 earnings results on Thursday, May 5, 2022 at 01:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores
April 05, 2022
Argenx SE (NASDAQ: ARGX) announced
Via
Benzinga
Golden Cross Appears Before argenx Investors
May 16, 2022
If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022
May 03, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
April 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
April 01, 2022
From
argenx SE
Via
Business Wire
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
March 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.